Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Following a request received from the company, NICE will be undertaking an appraisal of SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]. The appraisal is expected to start during early July 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-August 2023. The deadline for submissions is expected in approximately late-October 2023.
Process STA Standard
ID number 6280

Provisional Schedule

Expected publication 12 February 2025

Project Team

Project lead Vonda Murray

Email enquiries

Stakeholders

Companies sponsors ALK-Abello (SQ HDM SLIT)
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
  Welsh Government
Patient carer groups Allergy UK
  Asthma + Lung UK
  Fifth Sense
  Anaphylaxis UK
Professional groups Association of Respiratory Nurse Specialists
  British Paediatric Allergy, Immunity and Infection Group (BPAIIG)
  British Society for Allergy & Clinical Immunology
  British Thoracic Society
  British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN)
  ENT UK
  National Heart and Lung Institute
  Royal College of Physicians
  Royal Society of Medicine - Allergy and Immunology Section
Comparator companies AstraZeneca (benralizumab, tezepelumab) - (confidentiality agreement not signed, not participating)
  GlaxoSmithKline (mepolizumab) - (confidentiality agreement not signed, not participating)
  Novartis (omalizumab) - (confidentiality agreement not signed, not participating)
  Sanofi (dupilumab) - (confidentiality agreement not signed, not participating)
  Teva (reslizumab) - (confidentiality agreement not signed, not participating)
Evidence review group Centre for Reviews and Dissemination and Centre for Health Economics – York
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
12 November 2024 Committee meeting: 2
13 June 2024 - 16 September 2024 Draft guidance
14 May 2024 Committee meeting: 1
14 May 2024 Declaration of interests
23 August 2023 Invitation to participate
23 August 2023 In progress. In progress
21 June 2023 Awaiting development. Following a request received from the company, NICE will be undertaking an appraisal of SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]. The appraisal is expected to start during early July 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-August 2023. The deadline for submissions is expected in approximately late-October 2023.

For further information on our processes and methods, please see our CHTE processes and methods manual